Hemophilia B is treated primarily by replacing or compensating for the missing clotting protein, factor IX, that the body fails to produce in adequate amounts. Treatment ranges from regular infusions of factor IX concentrates to newer options like gene therapy and non-factor medications. The approach depends largely on severity: people with less than 1% of normal factor IX levels have severe disease, those with 1% to 5% have moderate disease, and those with 6% to 49% have mild hemophilia B.
Factor IX Replacement Therapy
The cornerstone of hemophilia B treatment is factor IX replacement, which delivers the missing clotting protein directly into the bloodstream through an intravenous infusion. These products come in two main forms: plasma-derived concentrates (made from donated blood) and recombinant concentrates (manufactured in a lab without human blood). Both work the same way, raising factor IX levels enough for blood to clot normally.
How much factor IX you need depends on what you’re treating. For a minor bleed like an uncomplicated joint bleed or shallow muscle bruise, the goal is to raise factor IX activity to 20% to 30% of normal, typically for one to two days. Moderate bleeds, such as deeper muscle injuries, mouth bleeds, or dental extractions, require levels of 25% to 50% for roughly two to seven days. Major bleeds involving the throat, central nervous system, or surgical sites call for levels of 50% to 100% maintained over seven to ten days. Doses are calculated based on body weight and how well a person’s body responds to the infusion.
Prophylaxis vs. On-Demand Treatment
People with hemophilia B can treat bleeds as they happen (on-demand therapy) or take regular infusions to prevent bleeds in the first place (prophylaxis). The difference in outcomes is dramatic. In a clinical study comparing the two approaches, patients on on-demand therapy experienced a median annualized bleeding rate of about 34 bleeds per year, while those receiving prophylaxis at 100 IU/kg once weekly had a median of just 2 bleeds per year.
Prophylaxis is now considered the standard of care for people with moderate to severe hemophilia B, especially children. The recommended starting regimen is 100 IU/kg once weekly, adjusted over time based on individual response. By keeping factor IX levels consistently above a protective threshold, prophylaxis prevents the repeated joint bleeds that, over years, cause permanent damage to cartilage and bone. This kind of progressive joint destruction is one of the most significant long-term consequences of undertreated hemophilia B.
Extended Half-Life Products
Standard factor IX concentrates are cleared from the body relatively quickly, which is why frequent infusions are necessary. Extended half-life products were developed to solve this problem. These are modified versions of factor IX that stay active in the bloodstream longer, allowing less frequent dosing while maintaining protective clotting levels.
Three extended half-life factor IX products are currently available. One fuses factor IX to albumin (a blood protein), another attaches it to an Fc protein fragment, and a third uses a polyethylene glycol modification. All three reduce the number of infusions a person needs, which is a meaningful quality-of-life improvement for someone who has been infusing multiple times a week since childhood. The exact dosing schedule varies by product and individual, but many people on extended half-life prophylaxis infuse every 7 to 14 days rather than every few days.
Gene Therapy
Gene therapy represents a fundamentally different treatment strategy. Instead of repeatedly replacing the missing protein, it delivers a working copy of the factor IX gene into the body’s cells so they can produce the protein on their own. For hemophilia B, this involves a single intravenous infusion of a viral vector carrying the corrected gene, which then directs liver cells to manufacture factor IX.
Results from the pivotal phase 3 trial were striking. After a single infusion, 96% of participants were able to stop their regular factor IX prophylaxis entirely. Factor IX activity levels rose by an average of 34.3 percentage points above baseline at 18 months, and the number of factor IX infusions patients needed dropped by 97%. For many participants, this meant going from weekly infusions to essentially none.
Gene therapy is not without limitations. It requires careful screening beforehand, particularly for pre-existing antibodies against the viral vector used to deliver the gene. Long-term durability beyond a few years is still being tracked, and the treatment carries a high upfront cost. But for eligible adults with severe or moderately severe hemophilia B, it offers the possibility of years without routine infusions.
Non-Factor Therapies
A newer class of treatments works not by replacing factor IX but by rebalancing the clotting system through a different mechanism. One FDA-approved option in this category lowers the levels of antithrombin, a natural protein that normally slows down clotting. By reducing antithrombin activity, the treatment allows more thrombin (a key clotting enzyme) to be generated, partially compensating for the missing factor IX.
This type of therapy is given as a subcutaneous injection rather than an intravenous infusion, which is a significant practical advantage. It was studied in both hemophilia A and hemophilia B patients, including those with and without inhibitors. Dosing is adjusted over time based on periodic blood tests measuring antithrombin levels. For people who struggle with venous access or want fewer IV infusions, subcutaneous non-factor therapy can meaningfully simplify daily life.
Managing Inhibitors
A small percentage of people with hemophilia B, roughly 1% to 5%, develop inhibitors. These are antibodies the immune system creates against the infused factor IX, essentially neutralizing the treatment. Inhibitors occur almost exclusively in people with severe hemophilia B caused by mutations that result in zero natural factor IX production.
When inhibitors are present, standard factor IX replacement no longer works. Treatment shifts to bypassing agents, which activate the clotting cascade through alternative pathways that don’t require factor IX at all. Two types exist: activated prothrombin complex concentrates and recombinant activated factor VII. Both can control bleeding, though they are less predictable than direct factor replacement and require careful dosing.
Inhibitor development in hemophilia B can also trigger severe allergic reactions to factor IX infusions, including anaphylaxis. This makes inhibitor management in hemophilia B more complex than in hemophilia A, where inhibitors are more common but allergic reactions are rare. People who develop inhibitors typically need to work with a specialized hemophilia treatment center to find the safest and most effective regimen.
How Severity Shapes Treatment
Not everyone with hemophilia B needs the same level of intervention. People with mild disease (6% to 49% factor IX activity) may only need treatment before surgery or after significant injuries. They rarely bleed spontaneously and can often go long stretches without any therapy.
Moderate hemophilia B (1% to 5% activity) is more variable. Some people bleed frequently enough to benefit from prophylaxis, while others manage well with on-demand treatment. The decision often comes down to bleeding patterns, joint health, and activity level.
Severe hemophilia B (less than 1% activity) almost always requires regular prophylaxis starting in early childhood. Without it, spontaneous bleeding into joints and muscles occurs frequently and leads to cumulative damage over time. For this group, the full range of treatment options, from extended half-life factor products to gene therapy to non-factor therapies, is most relevant.